Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease Export

@article{citeulike:3753687, abstract = {Alzheimer disease (AD) is the most common cause of dementia. Currently available therapies only provide symptomatic relief. A number of therapeutic approaches are under development that aim to increase the clearance of brain A03B2 peptides. These include immune mediated clearance of A03B2 and the inhibition of the interaction between A03B2 and its pathological chaperones. Both active and passive immunization has been shown to have robust effects in transgenic mouse models of AD on amyloid reduction and behavioral improvements. However, a human trial of active immunization has been associated with significant toxicity in a minority of patients. New generation vaccines are being developed which likely will reduce the potential for cell-mediated toxicity. In addition, the recent development of anti-chaperone therapy opens a new therapeutic avenue which is unlikely to be associated with toxicity.}, address = {Department of Neurology, New York University School of Medicine.; Department of Pathology, New York University School of Medicine.; Department of Psychiatry, New York University School of Medicine.}, author = {Wisniewski, Thomas and Frangione, Blas}, citeulike-article-id = {3753687}, citeulike-linkout-0 = {http://dx.doi.org/10.1111/j.1750-3639.2005.tb00102.x}, citeulike-linkout-1 = {http://www3.interscience.wiley.com/cgi-bin/abstract/118706689/ABSTRACT}, doi = {10.1111/j.1750-3639.2005.tb00102.x}, journal = {Brain Pathology}, keywords = {alzheimers, amyloid, qs21}, number = {1}, pages = {72--77}, posted-at = {2008-12-07 20:20:39}, priority = {2}, title = {Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease}, url = {http://dx.doi.org/10.1111/j.1750-3639.2005.tb00102.x}, volume = {15}, year = {2005} }

TY - JOUR ID - citeulike:3753687 L3 - citeulike-article-id:3753687 N2 - Alzheimer disease (AD) is the most common cause of dementia. Currently available therapies only provide symptomatic relief. A number of therapeutic approaches are under development that aim to increase the clearance of brain A03B2 peptides. These include immune mediated clearance of A03B2 and the inhibition of the interaction between A03B2 and its pathological chaperones. Both active and passive immunization has been shown to have robust effects in transgenic mouse models of AD on amyloid reduction and behavioral improvements. However, a human trial of active immunization has been associated with significant toxicity in a minority of patients. New generation vaccines are being developed which likely will reduce the potential for cell-mediated toxicity. In addition, the recent development of anti-chaperone therapy opens a new therapeutic avenue which is unlikely to be associated with toxicity. IS - 1 JF - Brain Pathology AD - Department of Neurology, New York University School of Medicine.; Department of Pathology, New York University School of Medicine.; Department of Psychiatry, New York University School of Medicine. EP - 77 TI - Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease VL - 15 SP - 72 KW - alzheimers KW - amyloid KW - qs21 AU - Wisniewski, Thomas AU - Frangione, Blas PY - 2005/// UR - http://dx.doi.org/10.1111/j.1750-3639.2005.tb00102.x ER -